115 related articles for article (PubMed ID: 9192735)
1. Renaturation, purification, and characterization of human plasminogen activator inhibitor type 2 (PAI-2) accumulated at high level in Escherichia coli.
Zhou A; Jiang X; Dou F; Zhu D; Xu X
J Biochem; 1997 May; 121(5):930-4. PubMed ID: 9192735
[TBL] [Abstract][Full Text] [Related]
2. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
Lawrence D; Strandberg L; Grundström T; Ny T
Eur J Biochem; 1989 Dec; 186(3):523-33. PubMed ID: 2514093
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms.
Mikus P; Urano T; Liljeström P; Ny T
Eur J Biochem; 1993 Dec; 218(3):1071-82. PubMed ID: 7506655
[TBL] [Abstract][Full Text] [Related]
4. High-level expression of active human plasminogen activator inhibitor type 1 (PAI-1) in E. coli.
Zhou A; Pei Y; Wu H; Dong X; Xu X
Biochem Mol Biol Int; 1996 May; 39(2):235-42. PubMed ID: 8799449
[TBL] [Abstract][Full Text] [Related]
5. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
6. [Biological function of fusion protein ATF-PAI2CD].
Wang X; Li P; Zhang YQ; Hou M; Sun XH; Tan L; Zhu YS
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Jul; 35(7):624-8. PubMed ID: 12883632
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
9. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2.
Medcalf RL; Stasinopoulos SJ
FEBS J; 2005 Oct; 272(19):4858-67. PubMed ID: 16176260
[TBL] [Abstract][Full Text] [Related]
10. Purification and characterisation of plasminogen activator inhibitor 2 produced in Saccharomyces cerevisiae.
Steven J; Cottingham IR; Berry SJ; Chinery SA; Goodey AR; Courtney M; Ballance DJ
Eur J Biochem; 1991 Mar; 196(2):431-8. PubMed ID: 1901039
[TBL] [Abstract][Full Text] [Related]
11. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
13. Analysis of serpin inhibitory function by mutagenesis of ovalbumin and generation of chimeric ovalbumin/PAI-2 fusion proteins.
McCarthy BJ; Worrall DM
J Mol Biol; 1997 Apr; 267(3):561-9. PubMed ID: 9126838
[TBL] [Abstract][Full Text] [Related]
14. Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies.
Lee HJ; Im H
Protein Expr Purif; 2003 Sep; 31(1):99-107. PubMed ID: 12963346
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD
Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways.
Schnaper HW; Barnathan ES; Mazar A; Maheshwari S; Ellis S; Cortez SL; Baricos WH; Kleinman HK
J Cell Physiol; 1995 Oct; 165(1):107-18. PubMed ID: 7559792
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of recombinant plasminogen activator inhibitor-1 from Escherichia coli.
Reilly TM; Seetharam R; Duke JL; Davis GL; Pierce SK; Walton HL; Kingsley D; Sisk WP
J Biol Chem; 1990 Jun; 265(16):9570-4. PubMed ID: 2188980
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Baker MS; Bleakley P; Woodrow GC; Doe WF
Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
[TBL] [Abstract][Full Text] [Related]
19. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
20. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.
Cochran BJ; Gunawardhana LP; Vine KL; Lee JA; Lobov S; Ranson M
BMC Biotechnol; 2009 May; 9():43. PubMed ID: 19442270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
